SCHEMBL25875993

SCHEMBL25875993

COC(=O)C1(OC)CCC(c2nc(Cl)c3cnn(CC(F)F)c3n2)CC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 1/20 0.33
ADORA1 P30542 1/20 0.32
PDE4A P27815 2/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
JAK2 O60674 1/20 0.32
RET P07949 1/20 0.32
KIF5B P33176 1/20 0.32
KDR P35968 1/20 0.32
FLT3 P36888 1/20 0.32
CCDC6 Q16204 1/20 0.32
LRRK2 Q5S007 5/20 0.31
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HSP90AA1 P07900 3/20 0.31
TRAP1 Q12931 3/20 0.31
HSP90AB1 P08238 1/20 0.31
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25876233 0.89 MAT2A (0.33) MAT2APDE4APDE4BPDE4CPDE4D
SCHEMBL25875942 0.89 MAT2A (0.42) MAT2APDE4BLRRK2
SCHEMBL25876299 0.87 LRRK2 (0.36) MAT2APDE4APDE4BPDE4CPDE4D
SCHEMBL25876077 0.87 MERTK (0.35) MAT2APDE4APDE4BPDE4CPDE4D
SCHEMBL25876275 0.87 PDE1A (0.36) MAT2APDE4APDE4BPDE4CPDE4D
SCHEMBL25876041 0.86 MAT2A (0.35) MAT2APDE4APDE4BPDE4CPDE4D
SCHEMBL25875863 0.83 PDE2A (0.41) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL25876131 0.82 PDE9A (0.34) PDE10A
SCHEMBL25875902 0.82 DGAT1 (0.33) MAT2APDE4APDE4BPDE4CPDE4D
SCHEMBL25876051 0.80 PDE9A (0.35) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234954-A1 COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF TYK MEDICINES, INC. (CN) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234954-A1 COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF RET, ROR1, FGFR3 MAT2A 686/4885ADORA1 2370/4885PDE4A 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.